# Ph 2 Elacestrant in ER Positive Uterine Sarcomas

> **NCT07467772** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 30 (estimated)

## Conditions studied

- Uterine Sarcoma
- Uterine Leiomyosarcoma
- Endometrial Stromal Sarcoma
- ESS
- Perivascular Epithelioid Cell Tumors
- Uterine Adenosarcoma
- Uterine PEComa
- Estrogen Receptor Positive Tumor
- uLMS

## Interventions

- **DRUG:** Elacestrant

## Key facts

- **NCT ID:** NCT07467772
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2027-07
- **Final completion:** 2028-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07467772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07467772, "Ph 2 Elacestrant in ER Positive Uterine Sarcomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07467772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*